Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
0.8EUR
176.29 MEUR
2.67 BEUR
157.69 M
About HIKMA PHARMACEUTICALS ORD GBP0.10
Sector
CEO
Riad Mishlawi
Headquarters
London
Website
Employees (FY)
9.1 K
Founded
1978
ISIN
GB00B0LCW083
FIGI
BBG000KRDHB3
Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
Depending on the exchange, the stock ticker may vary. For instance, on FWB exchange HIKMA PHARMACEUTIC.LS-,10 stocks are traded under the ticker H5P.
We've gathered analysts' opinions on HIKMA PHARMACEUTIC.LS-,10 future price: according to them, H5P price has a max estimate of 32.84 EUR and a min estimate of 21.99 EUR. Watch H5P chart and read a more detailed HIKMA PHARMACEUTIC.LS-,10 stock forecast: see what analysts think of HIKMA PHARMACEUTIC.LS-,10 and suggest that you do with its stocks.
Yes, you can track HIKMA PHARMACEUTIC.LS-,10 financials in yearly and quarterly reports right on TradingView.
HIKMA PHARMACEUTIC.LS-,10 is going to release the next earnings report on Aug 8, 2024. Keep track of upcoming events with our Earnings Calendar.
H5P net income for the last quarter is 54.31 M EUR, while the quarter before that showed 123.62 M EUR of net income which accounts for −56.07% change. Track more HIKMA PHARMACEUTIC.LS-,10 financial stats to get the full picture.
HIKMA PHARMACEUTIC.LS-,10 dividend yield was 3.17% in 2023, and payout ratio reached 81.97%. The year before the numbers were 2.92% and 66.56% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
As of May 16, 2024, the company has 9.10 K employees. See our rating of the largest employees — is HIKMA PHARMACEUTIC.LS-,10 on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HIKMA PHARMACEUTIC.LS-,10 EBITDA is 618.68 M EUR, and current EBITDA margin is 23.72%. See more stats in HIKMA PHARMACEUTIC.LS-,10 financial statements.
Like other stocks, H5P shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HIKMA PHARMACEUTIC.LS-,10 stock right from TradingView charts — choose your broker and connect to your account.